ENTA’s CC had many more analyst questions than any of the company’s prior CCs. Not sure why, but I suppose it’s a good sign. (I’ve listened to every ENTA CC since the 2013 IPO.) CC transcript: https://finance.yahoo.com/m/9d9f7e29-6d00-3518-93e7-d65594b4895d/enanta-pharmaceuticals-inc.html